This is an exciting and interesting time in the cell and gene therapy industry. The science is moving ahead as industry industrializes and standardizes the manufacturing and commercialization of products. Cell and gene therapy products are transforming the treatment of cancers and genetic diseases, as well as expanding into other areas of medicine including autoimmune diseases, cardiovascular diseases, musculoskeletal disease, dermatological diseases, and many others. Cell Therapy and Gene Therapy Markets presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

• Cell and Gene Therapy Market Summary by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
• Cell and Gene Therapy Market Summary by Method, 2020-2030 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
• Cell and Gene Therapy Market Summary by Geographical Region, 2020-2030 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
• Cell and Gene Therapy Market Summary for United States by Product Segment, 2020-2030 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
• U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
• Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
• Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
• Estimated Cell and Gene Therapy Sales by Leading Competitor, 2019 Sales ($ millions)

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary. The following conditions/disorders are covered:

• Dermatology, including:
  • Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Skin cells)
  • Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
  • Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
• Cardiovascular and Blood Disorders, including:
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
  • Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)
• Oncology, including:
  • Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
  • Oncology Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
  • Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, ROW)
  • Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
• Ophthalmic Conditions, including:
  • Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
  • Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2020 and Projected 2025, 2030 ($ millions) (United States, Europe, Other countries)
• Musculoskeletal Conditions and Disorders, including:
  • Musculoskeletal Cell Therapy Market, Estimated 2020 and Projected 2025 and 2030 ($ millions)
  • Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2020, Projected 2025 and 2030 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
  • Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
  • Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2019 ($ millions)
• Other Conditions, including:
  • Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2020 and Projected 2025 and 2030 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
  • Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2020, Projected 2025 and 2030 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)

Cell Therapy and Gene Therapy Markets also includes several discussions on cell and gene therapies in development and the impact these are expected to have on the market. Throughout the report, several market indicators, trends, and barriers are discussed. The report comments on the current COVID-19 cell and gene therapy pipeline. There are a number of companies that are responding to the call to develop a therapeutic or vaccine for the coronavirus, including:

• Vitro Biopharma
• Celularity and Sorrento Therapeutics
• CanSino Biologics
• Mesoblast
• Acturus Therapeutics
• Entos Pharmaceuticals
• Zydus Cadila
• AlloVir and Baylor College of Medicine
• Athersys
• Exothera
• Sirnaomics
• Mesoblast

The leading influencers in the market are those which have become first-to-market participants in the cell and gene therapy segment, have new developments which may disrupt current market conditions, and/or have an extensive pipeline sure to impact the market in the long-term forecast:

• Advantagene
• Advaxis
• AlloSource
• Alnylam Pharmaceuticals
• Amgen
• AnGes USA
• Anterogen
• Atara Therapeutics
• Athersys
• AveXis
• BioCardia
• BioMarin Pharmaceuticals
• Bluebird bio
• BrainStorm Cell Therapeutics
• Caladrius Bioscience
• Celyad
• Cook MyoSite
• Cytori Therapeutics
• Dendreon
• Ferring Pharmaceuticals
• Fibrocell
• Gamida Cell
• GenSight Biologics
• Genzyme
• Gilead Sciences
• Gradalis
• Inovio Pharmaceuticals
• Kiadis Pharma
• Medeor Therapeutics
• Medipost
• Merck
• Mesoblast
• MolMed
• Neurotech USA
• Nightstar Therapeutics
• Northwest Biotherapeutics
• Novartis
• NuVasive
• Orchard Therapeutics
• Organogenesis
• Orthofix
• Osiris Therapeutics (part of Smith & Nephew)
• Pharmicell
• Pluristem Therapeutics
• Quark Pharmaceuticals
• Renova Therapeutics
• Sanofi Pasteur
• SOTIO
• Spark Therapeutics
• Tessa Therapeutics
• Tocagen
• uniQure
• VBL Therapeutics
• ViroMed

Because gene therapies are currently not available in any wide capacity, there is little precedent upon which to base forecasts. Dollar figures represent the estimated global market for 2019 and expected market for 2020 based on first quarter company reports and is expressed in current dollars. Forecasts are provided through 2025 and an extended forecast for 2030. The size of each market segment refers to manufacturers’ revenues.